### THURSDAY, 23rd OF OCTOBER 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 - 7:45</td>
<td><strong>Continental Breakfast</strong></td>
<td>Ballroom Lobby</td>
<td>All presentations take place in the Ballroom</td>
</tr>
<tr>
<td>7:45 - 8:00</td>
<td><strong>Welcome and Opening Remarks</strong></td>
<td></td>
<td>• Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market</td>
</tr>
<tr>
<td></td>
<td><strong>Psychotropic New Drug Update</strong></td>
<td></td>
<td>• List key trends in new drug development</td>
</tr>
<tr>
<td>8:00 - 9:00</td>
<td><strong>PTSD Treatment Approaches Update</strong></td>
<td></td>
<td>• Describe current trends for treatment of non-combative PTSD</td>
</tr>
<tr>
<td></td>
<td><strong>Schizophrenia Update</strong></td>
<td></td>
<td>• Examine the differences between combative and non-combative treatment regimens for PTSD</td>
</tr>
<tr>
<td>9:00 - 10:00</td>
<td><strong>Clozapine Medicaid Data</strong></td>
<td></td>
<td>• Describe data summarizing current trends in treatment for schizophrenia</td>
</tr>
<tr>
<td></td>
<td><strong>What Comes After Clozapine?</strong></td>
<td></td>
<td>• Describe current data in relation to the use of clozapine</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td><strong>Break</strong></td>
<td>Refreshments in Ballroom Lobby</td>
<td>• Discuss the scope of cultural and diversity competency</td>
</tr>
<tr>
<td>10:15 - 10:45</td>
<td><strong>Diversity of Psychiatric Pharmacotherapy: Treatment Differences Between Ethnic Groups</strong></td>
<td></td>
<td>• Describe potential functional gains demonstrated by atypical antipsychotics</td>
</tr>
<tr>
<td></td>
<td><strong>Pediatric Psychopharmacology: The Surge in Autism</strong></td>
<td></td>
<td>• Cite evidence supporting the cognitive benefits of antipsychotics</td>
</tr>
<tr>
<td>11:15 - 11:45</td>
<td><strong>Panel Discussion on Schizophrenia Treatment</strong></td>
<td></td>
<td>• Explain alternative treatments of Schizophrenia</td>
</tr>
<tr>
<td>11:45 - 12:15</td>
<td><strong>Lunch</strong></td>
<td>Buffet in Ballroom Lobby, Seating in Rooms Across Hall</td>
<td>• Describe cognitive therapy approaches in relation to pharmacotherapy treatments</td>
</tr>
<tr>
<td>12:15 - 1:00</td>
<td><strong>Break</strong></td>
<td>Refreshments in Ballroom Lobby</td>
<td>• Discuss various current trends in treatments and alternative treatments</td>
</tr>
<tr>
<td>1:00 - 2:00</td>
<td><strong>Pediatric Psychopharmacology Update</strong></td>
<td></td>
<td>• Discuss recent advances in pediatric psychopharmacology</td>
</tr>
<tr>
<td></td>
<td><strong>Geriatric Psychopharmacology Update</strong></td>
<td></td>
<td>• Discuss recent advances in pharmacotherapy for youth with mental disorders</td>
</tr>
<tr>
<td>4:15 - 5:15</td>
<td><strong>Geriatric Psychopharmacology Update</strong></td>
<td></td>
<td>• Delineate current controversies with regard to the use of psychotropic medications in youth</td>
</tr>
<tr>
<td>5:15 - 6:30</td>
<td><strong>Reception</strong></td>
<td>Dover’s Room</td>
<td>• Describe recent advances in geriatric psychopharmacology</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Discuss recent advances in pharmacotherapy for elderly with mental disorders</td>
</tr>
</tbody>
</table>
## FRIDAY, 24TH OF OCTOBER 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 - 7:45</td>
<td>Welcome and Announcements</td>
<td>Ballroom Lobby</td>
<td>• Identify paradigm shifts in the assessment / treatment of bipolar disorder</td>
</tr>
<tr>
<td></td>
<td><strong>Stephen R. Saklad, Pharm.D., BCPP</strong></td>
<td></td>
<td>• Describe new treatment strategies in the treatment of bipolar disorder</td>
</tr>
<tr>
<td></td>
<td><strong>Psychiatric Pharmacotherapy Update Conference Chair</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:45 - 8:00</td>
<td>Antidepressants in Bipolar Disorder Patients with Depression</td>
<td></td>
<td>• Describe effective strategies for assessment of patients with characteristics indicative of bipolar depression</td>
</tr>
<tr>
<td></td>
<td><strong>Charles L. Bowden, MD</strong></td>
<td></td>
<td>• List the clinical consequences of anxiety associated with bipolar disorders</td>
</tr>
<tr>
<td></td>
<td><strong>Clinical Professor of Psychiatry &amp; Pharmacology</strong></td>
<td></td>
<td>• Identify differences in effectiveness of interventions for bipolar depression</td>
</tr>
<tr>
<td></td>
<td><strong>Nancy U. Karren Endowed Chair of Psychiatry</strong></td>
<td></td>
<td>• Describe combination regimen drug treatments for bipolar depression</td>
</tr>
<tr>
<td></td>
<td><strong>University of Texas Health Science Center San Antonio</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 9:00</td>
<td>Medical Marijuana Update <strong>(CME Ethics Credit)</strong></td>
<td></td>
<td>• Describe the evidence for medical use of cannabis</td>
</tr>
<tr>
<td></td>
<td><strong>Igor Grant, Ph.D.</strong></td>
<td></td>
<td>• Discuss untoward effects of the use of medical marijuana</td>
</tr>
<tr>
<td></td>
<td><strong>Distinguished Professor and Chair</strong></td>
<td></td>
<td>• Discuss ethical issues regarding use of cannabis</td>
</tr>
<tr>
<td></td>
<td><strong>Department of Psychiatry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>University of California San Diego School of Medicine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 - 10:00</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Break</td>
<td>Refreshments in Ballroom Lobby</td>
<td></td>
</tr>
<tr>
<td>10:15 - 11:15</td>
<td>Old Drugs, New Drugs: Changing Patterns of Use and Abuse <strong>(CME Ethics Credit)</strong></td>
<td></td>
<td>• Describe the emerging drugs (both new ones and emergence of old drugs) and changes over time</td>
</tr>
<tr>
<td></td>
<td><strong>Jane Maxwell, Ph.D.</strong></td>
<td></td>
<td>• Discuss treatment options and the need to get creditable information on harms out concerning these new drugs</td>
</tr>
<tr>
<td></td>
<td><strong>Senior Research Scientist, Addiction Research Institute</strong></td>
<td></td>
<td>• Discuss ethical dilemmas practitioners face when a patients substitutes illegal substances for prescription drugs</td>
</tr>
<tr>
<td></td>
<td><strong>Center for Social Work Research</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>The University of Texas at Austin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 - 12:15</td>
<td>Misuse of Legal Prescription Drugs <strong>(CME Ethics Credit)</strong></td>
<td></td>
<td>• Describe trends resulting in additions to prescription drugs</td>
</tr>
<tr>
<td></td>
<td><strong>Thomas Kosten, MD</strong></td>
<td></td>
<td>• Discuss methods to avoid addiction</td>
</tr>
<tr>
<td></td>
<td><strong>JH Waggoner Chair &amp; Professor of Psychiatry, Neuroscience, Pharmacology, Immunology, &amp; Pathology</strong></td>
<td></td>
<td>• Discuss treatment options to end addiction</td>
</tr>
<tr>
<td></td>
<td><strong>Baylor Medical School Houston</strong></td>
<td></td>
<td>• Describe ethical issues in trends with prescription drug addiction</td>
</tr>
<tr>
<td>12:15 - 12:30</td>
<td>Working Lunch</td>
<td>Pick up lunch in ballroom lobby and Return to ballroom for lunchtime panel</td>
<td></td>
</tr>
<tr>
<td>12:30 - 1:30</td>
<td>Ethics and Issues of Addiction Panel <strong>(CME Ethics Credit)</strong></td>
<td></td>
<td>• Identify the various ethical issues facing practitioners in the treatment of addiction</td>
</tr>
<tr>
<td></td>
<td><strong>Thomas Kosten, MD</strong></td>
<td></td>
<td>• Discuss the similarities of behaviors leading to addiction among various mental disorders, and similarities in treatments</td>
</tr>
<tr>
<td></td>
<td><strong>Jane Maxwell, Ph.D.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Igor Grant</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 - 2:30</td>
<td>Medication Management for Patients with Psychiatric Disorders in Primary Care</td>
<td></td>
<td>• Describe a patient-centered, team approach to mental health care in primary care</td>
</tr>
<tr>
<td></td>
<td><strong>Carla Cobb, Pharm.D., BCPP</strong></td>
<td></td>
<td>• Design an evidence-based medication regimen that fits the individual patient’s needs</td>
</tr>
<tr>
<td></td>
<td><strong>University of Montana</strong></td>
<td></td>
<td>• Evaluate the medication regimen to ensure that it is appropriate, effective, safe, and convenient</td>
</tr>
<tr>
<td>2:30 - 3:30</td>
<td>Dementia Update</td>
<td></td>
<td>• Describe recent changes and trends in the treatment of dementia</td>
</tr>
<tr>
<td></td>
<td><strong>Rajesh Tampi, MD, MS, FAPA</strong></td>
<td></td>
<td>• Discuss alternatives to antipsychotic therapy</td>
</tr>
<tr>
<td></td>
<td><strong>Associate Professor of Psychiatry</strong></td>
<td></td>
<td>• Describe side effects, Black Box Warnings, and other risks associated with antipsychotic therapy</td>
</tr>
<tr>
<td></td>
<td><strong>UT Health Science Center San Antonio</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30 - 3:45</td>
<td>CE Evaluation / Closing Remarks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CME Ethics Credit:** This event has been approved by the Texas Department of State Health Services, Continuing Education Service for 4 credits in medical ethics and/or professional responsibility